JP2018500332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500332A5 JP2018500332A5 JP2017532140A JP2017532140A JP2018500332A5 JP 2018500332 A5 JP2018500332 A5 JP 2018500332A5 JP 2017532140 A JP2017532140 A JP 2017532140A JP 2017532140 A JP2017532140 A JP 2017532140A JP 2018500332 A5 JP2018500332 A5 JP 2018500332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- dose
- ctla
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131637A JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092783P | 2014-12-16 | 2014-12-16 | |
| US62/092,783 | 2014-12-16 | ||
| US201562261130P | 2015-11-30 | 2015-11-30 | |
| US62/261,130 | 2015-11-30 | ||
| PCT/US2015/066177 WO2016100561A2 (en) | 2014-12-16 | 2015-12-16 | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131637A Division JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500332A JP2018500332A (ja) | 2018-01-11 |
| JP2018500332A5 true JP2018500332A5 (enExample) | 2019-01-31 |
Family
ID=56127849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532140A Pending JP2018500332A (ja) | 2014-12-16 | 2015-12-16 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
| JP2021131637A Pending JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131637A Pending JP2021181482A (ja) | 2014-12-16 | 2021-08-12 | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180133313A1 (enExample) |
| EP (1) | EP3233123A4 (enExample) |
| JP (2) | JP2018500332A (enExample) |
| CN (1) | CN106999590A (enExample) |
| BR (1) | BR112017010101A2 (enExample) |
| CA (1) | CA2969338A1 (enExample) |
| MX (1) | MX2017007390A (enExample) |
| RU (1) | RU2726996C1 (enExample) |
| WO (1) | WO2016100561A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| US11209441B2 (en) | 2016-04-05 | 2021-12-28 | Bristol-Myers Squibb Company | Cytokine profiling analysis |
| JP7250674B2 (ja) * | 2016-08-08 | 2023-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| GB201618291D0 (en) * | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
| AU2017372856B9 (en) * | 2016-12-05 | 2024-01-04 | Pharmacosmos Holding A/S | Preservation of immune response during chemotherapy regimens |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| DE102017119868B4 (de) * | 2017-07-12 | 2021-05-27 | Bruker Daltonik Gmbh | Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie |
| US10617667B2 (en) * | 2017-11-01 | 2020-04-14 | Ono Pharmaceutical Co., Ltd. | Method for treating brain tumors |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| JP7388635B2 (ja) | 2018-05-31 | 2023-11-29 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| EP3941467A4 (en) * | 2019-03-19 | 2022-12-21 | ChemoCentryx, Inc. | MULTIPLE THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR |
| WO2021050093A1 (en) * | 2019-09-10 | 2021-03-18 | Novocure Gmbh | A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells |
| JP7772700B2 (ja) * | 2019-12-19 | 2025-11-18 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 神経膠芽腫を処置するための方法 |
| CN114980930A (zh) * | 2019-12-27 | 2022-08-30 | 志瑞亚新药工业株式会社 | 癌症治疗方法及药物 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| JP2023526228A (ja) * | 2020-05-12 | 2023-06-21 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 膠芽腫を処置するための方法 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| US20230365690A1 (en) * | 2020-08-07 | 2023-11-16 | Northwestern University | Methods of treating malignant glioblastoma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2545609T3 (es) * | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| PL2342226T3 (pl) * | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| RU2402360C1 (ru) * | 2009-07-08 | 2010-10-27 | Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) | Способ лечения злокачественной глиомы головного мозга |
| CN102178676B (zh) * | 2011-04-29 | 2012-07-25 | 山东大学 | 一种治疗脑胶质瘤的药物组合物 |
| AU2012273182A1 (en) * | 2011-06-21 | 2014-01-16 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
-
2015
- 2015-12-16 RU RU2017125052A patent/RU2726996C1/ru active
- 2015-12-16 WO PCT/US2015/066177 patent/WO2016100561A2/en not_active Ceased
- 2015-12-16 MX MX2017007390A patent/MX2017007390A/es unknown
- 2015-12-16 JP JP2017532140A patent/JP2018500332A/ja active Pending
- 2015-12-16 EP EP15871017.8A patent/EP3233123A4/en not_active Withdrawn
- 2015-12-16 CA CA2969338A patent/CA2969338A1/en not_active Abandoned
- 2015-12-16 BR BR112017010101A patent/BR112017010101A2/pt not_active Application Discontinuation
- 2015-12-16 US US15/536,785 patent/US20180133313A1/en not_active Abandoned
- 2015-12-16 CN CN201580069022.6A patent/CN106999590A/zh active Pending
-
2020
- 2020-07-20 US US16/933,547 patent/US20210000953A1/en not_active Abandoned
-
2021
- 2021-08-12 JP JP2021131637A patent/JP2021181482A/ja active Pending
-
2023
- 2023-12-06 US US18/531,312 patent/US20240238416A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503387A5 (enExample) | ||
| Aglietta et al. | A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer | |
| JP2019517512A5 (enExample) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| KR102463617B1 (ko) | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 | |
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2018522887A5 (enExample) | ||
| JP2017507155A5 (enExample) | ||
| US10842743B2 (en) | Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents | |
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2018514550A5 (enExample) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| US10232040B2 (en) | Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer | |
| JP2018516969A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| HRP20181646T2 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| JP2019517505A5 (enExample) | ||
| JP2019522657A5 (enExample) | ||
| JP2022511337A5 (enExample) | ||
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2015525798A5 (enExample) | ||
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors |